Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines
Hernandez-Ilizaliturri F, Mavis C, Maraj I, Chisti M, Gibbs J, Czuczman M. Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines. Blood 2010, 116: 3936. DOI: 10.1182/blood.v116.21.3936.3936.Peer-Reviewed Original ResearchCell linesBcl-xLBcl-2 family proteinsBcl-2 family membersLymphoma cell linesProteasome inhibitorsRegulation of BakAnti-tumor activityLymphoma cellsB-cell lymphomaCellular processesFamily proteinsWestern blotGene transcriptionPan-caspaseHistone deacetylase inhibitorsSingle agentTarget proteinsCaspase inhibitionMolecular eventsAlamar Blue reductionMcl-1Mitochondrial potentialATP synthesisHodgkin's lymphoma cell lines